ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
1,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
1,3,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
3,1,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
4,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
5,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
6,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
7,1,Rash follicular,Pustular conditions,Epidermal and dermal conditions,Skin,N
8,1,Cheilitis,Oral soft tissue disorders NEC,Oral soft tissue conditions,Gastr,N
9,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
10,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
11,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
12,1,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
13,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
14,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
14,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
15,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
16,1,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
17,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
18,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
19,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
20,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
20,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
20,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
21,1,Cushing's syndrome,Adrenal cortical hyperfunctions,Adrenal gland disorders,Endo,N
22,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
22,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
23,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
24,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
25,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
25,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
26,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
27,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
27,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
28,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
28,2,Granuloma skin,Granulomatous and deep cutaneous inflammatory conditions,Epidermal and dermal conditions,Skin,N
28,3,Injection site nodule,Injection site reactions,Administration site reactions,Genrl,N
28,4,Keloid scar,Skin dystrophies,Cornification and dystrophic skin disorders,Skin,N
29,1,Application site swelling,Application site reactions,Administration site reactions,Genrl,N
30,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
31,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
31,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
31,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
31,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
31,5,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
31,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
32,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
33,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
33,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
34,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
34,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
34,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
35,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
35,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
36,1,Blood potassium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
36,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
36,3,Cardiac tamponade,Pericardial disorders NEC,Pericardial disorders,Card,N
37,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
37,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
37,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
38,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
38,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
38,3,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
39,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
39,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
40,1,Ammonia increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
40,2,Ornithine transcarbamoylase deficiency,Inborn errors of amino acid metabolism,Metabolic and nutritional disorders congenital,Cong,N
41,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
41,2,Creatinine renal clearance decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
42,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
42,2,Creatinine renal clearance decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
43,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
43,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
44,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
44,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
44,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
44,4,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
44,5,Thermal burn,Thermal burns,Injuries by physical agents,Inj&P,N
45,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
46,1,Citrate toxicity,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
47,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
48,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
49,1,Blood calcium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
49,2,Creutzfeldt-Jakob disease,Prion-associated disorders,Viral infectious disorders,Infec,N
49,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
49,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
49,5,Thrombosis in device,Device malfunction events NEC,Device issues,Prod,N
50,1,Application site discolouration,Application site reactions,Administration site reactions,Genrl,N
50,2,Application site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
50,3,Application site pustules,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
50,4,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
51,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
51,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
51,3,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
52,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
53,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
54,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
55,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
56,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
56,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
56,3,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
57,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
57,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
58,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
59,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
60,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
61,1,Hair growth abnormal,Pilar disorders NEC,Skin appendage conditions,Skin,N
62,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
62,2,Thrombosis in device,Device malfunction events NEC,Device issues,Prod,N
63,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
64,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
64,2,Thrombosis in device,Device malfunction events NEC,Device issues,Prod,N
65,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
66,1,Device occlusion,Device malfunction events NEC,Device issues,Prod,N
66,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
67,1,Azotaemia,Renal failure complications,Renal disorders (excl nephropathies),Renal,N
67,2,Haemodialysis complication,Dialysis related complications,Procedural related injuries and complications NEC,Inj&P,N
67,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
67,4,Hypervolaemia,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
67,5,Thrombosis in device,Device malfunction events NEC,Device issues,Prod,N
68,1,Excessive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
69,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
70,1,Escherichia bacteraemia,Escherichia infections,Bacterial infectious disorders,Infec,N
70,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
70,3,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
70,4,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
70,5,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
71,1,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
72,1,Device failure,Device issues NEC,Device issues,Prod,N
72,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
73,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
73,2,Shock,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
73,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
74,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
74,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
75,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
76,1,Device infusion issue,Device malfunction events NEC,Device issues,Prod,N
76,2,Device issue,Device issues NEC,Device issues,Prod,N
76,3,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
76,4,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
76,5,Incorrect drug administration rate,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
77,1,Blood calcium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
77,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
77,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
78,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
78,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
79,1,Application site haemorrhage,Application site reactions,Administration site reactions,Genrl,N
80,1,Application site vesicles,Application site reactions,Administration site reactions,Genrl,N
80,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
81,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
81,2,Accidental exposure to product by child,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
81,3,Tongue injury,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
81,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
82,1,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
82,2,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
82,3,Application site pain,Application site reactions,Administration site reactions,Genrl,N
82,4,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
83,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
84,1,Aesthesioneuroblastoma,Nervous system neoplasms malignant NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
84,2,Nasal congestion,Nasal congestion and inflammations,Upper respiratory tract disorders (excl infections),Resp,N
85,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
86,1,Eye pain,Ocular disorders NEC,Eye disorders NEC,Eye,N
86,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
86,3,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
86,4,Product packaging confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
86,5,Thermal burns of eye,Thermal burns,Injuries by physical agents,Inj&P,N
86,6,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
86,7,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
87,1,Application site discolouration,Application site reactions,Administration site reactions,Genrl,N
87,2,Application site induration,Application site reactions,Administration site reactions,Genrl,N
88,1,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
88,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
88,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
89,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
90,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
90,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
90,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
90,4,Headache,Headaches NEC,Headaches,Nerv,N
90,5,Hypopnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
90,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
91,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
91,2,Chemical burns of eye,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
92,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
92,2,Skin papilloma,Skin neoplasms benign,Cutaneous neoplasms benign,Neopl,N
93,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
93,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
94,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
95,1,Accidental exposure to product by child,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
95,2,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
95,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
96,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
96,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
97,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
97,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
98,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
98,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
99,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
99,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
99,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
100,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
100,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
100,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
101,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
101,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
101,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
102,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
103,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
104,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
104,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
104,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
105,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
106,1,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
107,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
107,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
108,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
108,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
109,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
109,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
109,3,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
110,1,Application site exfoliation,Application site reactions,Administration site reactions,Genrl,N
110,2,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
111,1,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
111,2,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
112,1,Product residue present,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
112,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
113,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
113,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
114,1,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
114,2,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
114,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
115,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
115,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
115,3,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
115,4,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
115,5,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
115,6,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
115,7,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
115,8,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
115,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
115,10,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
115,11,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
115,12,Lactic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
115,13,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
115,14,Limb injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
115,15,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
115,16,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
115,17,Myalgia,Muscle pains,Muscle disorders,Musc,N
115,18,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
115,19,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
115,20,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
116,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
116,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
116,3,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
117,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
117,2,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
117,3,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
117,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
117,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
117,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
118,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
118,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
119,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
119,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
120,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
120,2,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
121,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
121,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
121,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
122,1,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
122,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
122,3,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
123,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
123,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
124,1,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
125,1,Pigmentation disorder,Pigmentation changes NEC,Pigmentation disorders,Skin,N
125,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
126,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
126,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
127,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
127,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
128,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
128,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
128,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
129,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
130,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
130,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
131,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
131,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
132,1,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
132,2,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
133,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
134,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
134,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
135,1,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
135,2,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
136,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
137,1,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
137,2,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
138,1,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
139,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
139,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
139,3,Product adhesion issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
140,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
141,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
141,2,Product physical consistency issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
142,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
142,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
143,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
143,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
144,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
144,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
145,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
146,1,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
147,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
148,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
148,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
149,1,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
150,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
150,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
150,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
151,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
151,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
152,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
152,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
153,1,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
154,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
154,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
155,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
155,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
156,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
156,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
157,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
157,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
158,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
158,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
159,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
159,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
159,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
160,1,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
161,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
162,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
162,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
162,3,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
163,1,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
163,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
163,3,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
163,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
164,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
164,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
165,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
166,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
167,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
167,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
168,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
168,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
168,3,Product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
169,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
170,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
171,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
171,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
171,3,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
171,4,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
172,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
172,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
172,3,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
173,1,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
173,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
174,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
174,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
175,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
175,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
176,1,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
176,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
176,3,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
177,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
177,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
178,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
178,2,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
179,1,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
180,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
180,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
180,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
180,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
181,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
181,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
181,3,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
181,4,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
182,1,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
183,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
183,2,Product complaint,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
183,3,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
184,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
185,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
185,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
185,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
186,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
186,2,Lip pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
186,3,Product selection error,Product selection errors and issues,Medication errors and other product use errors and issues,Inj&P,N
187,1,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
187,2,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
188,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
188,2,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
189,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
190,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
191,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
191,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
192,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
192,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
192,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
193,1,Application site irritation,Application site reactions,Administration site reactions,Genrl,N
193,2,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
194,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
194,2,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
194,3,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
195,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
196,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
196,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
196,3,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
197,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
197,2,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
197,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
197,4,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
198,1,Chemical burn,Chemical injuries,"Exposures, chemical injuries and poisoning",Inj&P,N
199,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
199,2,Hyperaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
200,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
200,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
201,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
202,1,Neoplasm skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
202,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
203,1,Neoplasm skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
203,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
204,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
204,2,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
204,3,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
205,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
205,2,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
206,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
206,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
207,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
207,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
207,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
207,4,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
208,1,Application site scar,Application site reactions,Administration site reactions,Genrl,N
208,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
209,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
209,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
210,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
211,1,Application site haemorrhage,Application site reactions,Administration site reactions,Genrl,N
211,2,Application site pain,Application site reactions,Administration site reactions,Genrl,N
211,3,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
211,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
212,1,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
212,2,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
212,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
212,4,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
213,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
213,2,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
213,3,Incorrect product administration duration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
213,4,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
214,1,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
215,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
215,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
216,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
216,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
216,3,Skin discomfort,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
217,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
218,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
218,2,Product packaging difficult to open,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
218,3,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
219,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
219,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
220,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
220,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
221,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
222,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
222,2,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
222,3,Skin injury,Skin injuries NEC,Injuries NEC,Inj&P,N
222,4,Therapeutic product effect incomplete,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
223,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
223,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
224,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
225,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
226,1,Nail growth abnormal,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
227,1,Limb injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
227,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
228,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
228,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
229,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
229,2,Scar,Skin injuries NEC,Injuries NEC,Inj&P,N
230,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
230,2,Application site scar,Application site reactions,Administration site reactions,Genrl,N
230,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
231,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
231,2,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
232,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
232,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
232,3,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
233,1,Application site haemorrhage,Application site reactions,Administration site reactions,Genrl,N
234,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
234,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
235,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
235,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
235,3,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
235,4,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
236,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
237,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
237,2,Contraindicated product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
238,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
238,2,Skin haemorrhage,Skin haemorrhages,Skin vascular abnormalities,Skin,N
239,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
239,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
240,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
241,1,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
242,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
243,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
243,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
244,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,2,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
245,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
245,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
246,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
246,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
247,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
247,2,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
